A Historical Controlled, Single Center Open Label Pilot Study Comparing the Effectiveness and Tolerability of De Novo Initiation of Letermovir versus Valganciclovir for Cytomegalovirus Prophylaxis in African American Kidney Transplant Recipients (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.25; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; P3 | "Preliminary results suggest LET is an effective, well-tolerated alternative to VGC for CMV prophylaxis in high-risk AA KTRs. LET was associated with lower breakthrough CMV and leukopenia while maintaining comparable survival rates. Further follow-up is ongoing to confirm these initial findings."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Immunology • Infectious Disease • Leukopenia • Septic Shock • Transplant Rejection • Transplantation
|
|
I. Yakubu; G. Abebe; D. Kumar; A. Brown; I. Moinuddin; M. Morales; S. Sterling; A. Iaria; B. Agegnehu; R. Marks; M. Saeed; G. Gupta
|